Page 6 - Ivir News Today

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript August 3, 2023 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-1.45 EPS, expectations were $1.21. Operator: Hello. Welcome to Vir Biotechnology Second Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all […]

Vir Biotechnology (NASDAQ:VIR – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.24), Briefing.com reports. The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $22.39 million. During the same quarter last year, […]

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price cut by Barclays from $59.00 to $41.00 in a report released on Friday, MarketBeat.com reports. They currently have an overweight rating on the stock. Several other equities analysts have also weighed in on VIR. Morgan Stanley raised their price objective on shares of Vir Biotechnology […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its price objective lowered by Needham & Company LLC from $32.00 to $22.00 in a report released on Thursday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Other equities research analysts also recently issued reports about the stock. Morgan Stanley boosted […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its price target cut by Needham & Company LLC from $32.00 to $22.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Several other brokerages have also commented on VIR. SVB Securities dropped their price target on […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price cut by Morgan Stanley from $27.00 to $15.00 in a research report report published on Friday morning, Benzinga reports. They currently have an equal weight rating on the stock. A number of other equities analysts have also issued reports on VIR. TheStreet lowered shares of […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its price target cut by Needham & Company LLC from $32.00 to $22.00 in a report published on Thursday, Benzinga reports. They currently have a buy rating on the stock. VIR has been the topic of a number of other research reports. SVB Securities reduced their price objective […]

Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price decreased by The Goldman Sachs Group from $51.00 to $28.00 in a research note published on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other equities analysts also recently commented on VIR. Morgan Stanley increased their […]

Viridium Pacific Group Ltd (CVE:VIR – Get Free Report)’s stock price rose 5.6% on Friday . The stock traded as high as C$0.41 and last traded at C$0.38. Approximately 26,500 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 92,632 shares. The stock had previously closed at C$0.36. […]